BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...
New drugs and therapies have become indispensable for treating an array of cancers. Unfortunately, they can also cause damage to the heart, a side effect that has led to the development of a new ...
Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s ...
In a major discovery, scientists have presented the first evidence of Alzheimer's disease transmission in living individuals.
Those findings open the door to developing a diagnostic blood test that could replace invasive heart biopsies for patients suspected of having myocarditis. “It’s important to remember that ...
The findings open the door to developing a diagnostic blood test that could replace invasive heart biopsies for patients suspected of having myocarditis. The work also lends support to an ongoing ...